CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $17.83.

A number of brokerages recently commented on CVRX. William Blair raised CVRx from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 14th. Piper Sandler boosted their price objective on CVRx from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th. Canaccord Genuity Group increased their target price on CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, February 5th. Finally, Craig Hallum upped their price target on CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, January 17th.

Hedge Funds Weigh In On CVRx

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. PharVision Advisers LLC bought a new stake in shares of CVRx in the 4th quarter worth approximately $259,000. Two Sigma Investments LP increased its position in CVRx by 80.7% in the fourth quarter. Two Sigma Investments LP now owns 55,367 shares of the company’s stock worth $702,000 after buying an additional 24,734 shares during the period. Silvercrest Asset Management Group LLC bought a new stake in CVRx in the fourth quarter valued at $4,713,000. Parkman Healthcare Partners LLC boosted its holdings in shares of CVRx by 34.9% during the fourth quarter. Parkman Healthcare Partners LLC now owns 921,174 shares of the company’s stock valued at $11,671,000 after acquiring an additional 238,277 shares during the period. Finally, Cresset Asset Management LLC grew its position in shares of CVRx by 20.5% during the fourth quarter. Cresset Asset Management LLC now owns 51,102 shares of the company’s stock worth $647,000 after acquiring an additional 8,699 shares during the last quarter. 75.27% of the stock is currently owned by institutional investors and hedge funds.

CVRx Trading Down 0.8 %

NASDAQ CVRX opened at $12.60 on Friday. The company’s fifty day simple moving average is $14.23 and its 200-day simple moving average is $12.75. The stock has a market cap of $328.05 million, a P/E ratio of -4.68 and a beta of 1.34. CVRx has a 52 week low of $6.40 and a 52 week high of $19.24. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. Equities research analysts predict that CVRx will post -1.91 EPS for the current fiscal year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.